1.37

1.44% -0.02

After Hours: 1.37

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is traded at $1.37, with a volume of 578.06K. It is down -1.44% in the last 24 hours and up +20.18% over the past month. Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Previous Close:

$1.39

Open:

$1.38

24h Volume:

578.06K

Relative Volume:

0.47

Market Cap:

$96.86M

Revenue:

Net Income/Loss:

$-144.01M

P/E Ratio:

-0.3416

EPS:

-4.01

Net Cash Flow:

$-113.02M

1W Performance:

-5.52%

1M Performance:

+20.18%

6M Performance:

-28.65%

1Y Performance:

-52.92%

1-Day Range:

$1.33

$1.41

1-Week Range:

$1.245

$1.46

52-Week Range:

$0.8719

$3.08

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(650) 980-9099

Address

1599 INDUSTRIAL ROAD, SAN CARLOS

Employee

Twitter

Next Earnings Date

2025-05-02

Latest SEC Filings

BMEA's Discussions on Twitter

Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMEA Biomea Fusion Inc	1.37	98.28M	0	-144.01M	-113.02M	-4.01
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Aug-28-25	Initiated	Jefferies	Buy
Jun-03-25	Resumed	Piper Sandler	Overweight
Oct-09-24	Initiated	Edward Jones	Buy
Sep-27-24	Upgrade	Rodman & Renshaw	Neutral → Buy
Sep-27-24	Upgrade	Truist	Hold → Buy
Aug-29-24	Initiated	CapitalOne	Overweight
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

Mar 04, 2026

BMEA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 02, 2026